Hemagglutinin (H5N1 virus) (HA)

The H5N1 virus hemagglutinin (HA) is a critical surface glycoprotein that mediates the initial stages of influenza A virus infection by facilitating viral attachment and entry into host cells. It functions by binding to sialic acid-containing receptors on the host cell membrane, particularly those with alpha-2,3 linkages found in avian respiratory tracts and the human lower respiratory tract [1, 5, 9]. Following internalization via endocytosis, HA undergoes a low-pH-dependent conformational change that triggers the fusion of the viral envelope with the endosomal membrane, releasing the viral genome into the cytoplasm [9, 13, 15]. In the context of disease, the HA protein is a primary determinant of H5N1 pathogenicity and host range, with specific mutations in its cleavage site or receptor-binding domain enabling the virus to cause severe, often fatal, respiratory infections in humans [3, 10, 14]. As a therapeutic target, HA is the focus of both vaccine development and novel antiviral strategies, including small-molecule fusion inhibitors and broadly neutralizing antibodies [2, 7, 12]. While drugs like umifenovir (Arbidol) target HA-mediated fusion, the protein's high rate of mutation remains a significant challenge, necessitating the ongoing surveillance of antigenic variants to ensure treatment and vaccine efficacy [8, 11, 17].

Other names

H5 hemagglutininHemagglutinin proteinH5N1 HASurface glycoprotein HAHA0HA1HA2

Drugs targeting hemagglutinin primarily act as fusion inhibitors by stabilizing the prefusion conformation or blocking the pH-induced conformational change required for viral and endosomal membrane fusion [2, 7, 13]. Other mechanisms include blocking the receptor-binding site (RBS) to prevent attachment to host sialic acids and inhibiting the proteolytic cleavage of the precursor HA0 into its active HA1 and HA2 subunits [7, 13]. Additionally, broadly neutralizing antibodies can target the conserved stalk region to neutralize diverse influenza strains [2, 11].